Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX1 | P51575 | 3/20 | 0.72 |
| ▸ | P2RX4 | Q99571 | 3/20 | 0.72 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.72 |
| ▸ | TMPRSS4 | Q9NRS4 | 3/20 | 0.72 |
| ▸ | JAK2 | O60674 | 2/20 | 0.67 |
| ▸ | JAK1 | P23458 | 2/20 | 0.67 |
| ▸ | TYK2 | P29597 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 6/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.61 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.61 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.61 |
| ▸ | AVPR2 | P30518 | 2/20 | 0.60 |
| ▸ | GPR27 | Q9NS67 | 2/20 | 0.60 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 4/20 | 0.58 |
| ▸ | NPC1 | O15118 | 3/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12334655 | 0.87 | RORC (0.71) | P2RX1P2RX4P2RX7TMPRSS4JAK2 | |
| SCHEMBL25349155 | 0.87 | TMPRSS4 (0.80) | P2RX1P2RX4P2RX7TMPRSS4JAK2 | |
| SCHEMBL331631 | 0.84 | TMPRSS4 (1.00) | P2RX1P2RX4P2RX7TMPRSS4MEN1 | |
| SCHEMBL29617517 | 0.84 | TMPRSS4 (1.00) | P2RX1P2RX4P2RX7TMPRSS4MEN1 | |
| SCHEMBL24823602 | 0.83 | P2RX1 (0.69) | P2RX1P2RX4P2RX7TMPRSS4JAK2 | |
| SCHEMBL4511425 | 0.82 | P2RX1 (0.53) | P2RX1P2RX4P2RX7TMPRSS4JAK2 | |
| SCHEMBL5369677 | 0.82 | RORC (0.76) | P2RX1P2RX4P2RX7TMPRSS4JAK2 | |
| SCHEMBL14228391 | 0.81 | JAK2 (0.69) | P2RX1JAK2JAK1TYK2MEN1 | |
| SCHEMBL14113143 | 0.80 | TMPRSS4 (0.69) | P2RX1P2RX4P2RX7TMPRSS4JAK2 | |
| SCHEMBL1466665 | 0.80 | KCNK2 (0.58) | P2RX1P2RX4P2RX7TMPRSS4JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729101-B2 | 1H-imidazole derivative having CB1, agonistic, CB1 partial agonistic or CB1 antagnistic activity | SOLVAY PHARMACEUTICALS, B.V. (NL) | 2014-05-20 | — | — | US | disclosed |
| US-20090181949-A1 | 1H-IMIDAZOLE DERIVATIVE HAVING CB1, AGONISTIC, CB1 PARTIAL AGONISTIC OR CB1 ANTAGNISTIC ACTIVITY | SOLVAY PHARMACEUTICALS B.V. | 2009-07-16 | — | — | US | disclosed |
| EP-1438296-B1 | 1H-IMIDAZOLE DERIVATIVES HAVING CB1 AGONISTIC, CB1 PARTIAL AGONISTIC OR CB1- ANTAGONISTIC ACTIVITY | SOLVAY PHARM BV (NL) | 2008-11-26 | — | — | EP | disclosed |
| US-7109216-B2 | 1H-imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity | SOLVAY PHARMACEUTICALS B.V. (NL) | 2006-09-19 | — | — | US | disclosed |
| US-20050054679-A1 | 1 H-imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity | SOLVAY PHARMACEUTICALS B.V. | 2005-03-10 | — | — | US | disclosed |
| US-20040235854-A1 | 1H-imidazole derivatives having cb1 agonistic, cb1 partial agonistic or cb1 antagonistic activity | SOLVAY PHARMACEUTICALS B.V. (NL) | 2004-11-25 | — | — | US | disclosed |
| EP-1438296-A2 | 1H-IMIDAZOLE DERIVATIVES HAVING CB1 AGONISTIC, CB1 PARTIAL AGONISTIC OR CB1- ANTAGONISTIC ACTIVITY | Solvay Pharmaceuticals B.V. (NL) | 2004-07-21 | — | — | EP | disclosed |
| WO-2003027076-A2 | 1H-IMIDAZOLE DERIVATIVES HAVING CB1 AGONISTIC, CB1 PARTIAL AGONISTIC OR CB1- ANTAGONISTIC ACTIVITY | SOLVAY PHARMACEUTICALS B.V. (NL) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181949-A1 | 1H-IMIDAZOLE DERIVATIVE HAVING CB1, AGONISTIC, CB1 PARTIAL AGONISTIC OR CB1 ANTAGNISTIC ACTIVITY | CNR1, CNR2, CHRM1 | P2RX1 140/4885P2RX4 207/4885P2RX7 198/4885 |
| US-20040235854-A1 | 1H-imidazole derivatives having cb1 agonistic, cb1 partial agonistic or cb1 antagonistic activity | CNR1, CNR2, CHRM1 | P2RX1 188/4885P2RX4 262/4885P2RX7 254/4885 |
| US-20050054679-A1 | 1 H-imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity | CNR1, CNR2, HRH4 | P2RX1 186/4885P2RX4 267/4885P2RX7 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.